OnCo
trialsTrialCompleted

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

A phase 3 trial of Docetaxel, Trastuzumab, Epirubicin, Cyclophosphamide, Fluorouracil, Lenograstim and Pegfilgrastim in Breast cancer, run by Hellenic Oncology Research Group, completed.